Free Trial

United Therapeutics (UTHR) Competitors

United Therapeutics logo
$290.91 +3.56 (+1.24%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$292.50 +1.59 (+0.55%)
As of 09:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UTHR vs. ALNY, BIIB, INCY, NBIX, EXEL, BMRN, EXAS, RGEN, HALO, and MDGL

Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.

United Therapeutics vs. Its Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Alnylam Pharmaceuticals presently has a consensus target price of $340.00, indicating a potential upside of 5.57%. United Therapeutics has a consensus target price of $386.15, indicating a potential upside of 32.74%. Given United Therapeutics' higher probable upside, analysts clearly believe United Therapeutics is more favorable than Alnylam Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
20 Buy rating(s)
0 Strong Buy rating(s)
2.79
United Therapeutics
0 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.69

In the previous week, United Therapeutics had 5 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 30 mentions for United Therapeutics and 25 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.08 beat United Therapeutics' score of 1.03 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
14 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
United Therapeutics
19 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alnylam Pharmaceuticals has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 1.2% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$2.25B18.68-$278.16M-$2.09-154.10
United Therapeutics$2.88B4.56$1.20B$25.0611.61

United Therapeutics has a net margin of 40.44% compared to Alnylam Pharmaceuticals' net margin of -11.49%. United Therapeutics' return on equity of 19.33% beat Alnylam Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals-11.49% -510.31% -6.48%
United Therapeutics 40.44%19.33%16.73%

Summary

United Therapeutics beats Alnylam Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UTHR vs. The Competition

MetricUnited TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$12.96B$2.43B$5.48B$8.94B
Dividend YieldN/A1.79%5.38%4.12%
P/E Ratio11.618.7826.2219.74
Price / Sales4.56636.32394.92109.12
Price / Cash10.12154.3736.4957.06
Price / Book2.024.467.915.37
Net Income$1.20B$31.16M$3.15B$248.34M
7 Day Performance1.73%0.38%0.75%1.67%
1 Month Performance-10.62%8.14%3.46%4.56%
1 Year Performance-8.24%3.02%34.60%18.42%

United Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UTHR
United Therapeutics
4.9941 of 5 stars
$290.91
+1.2%
$386.15
+32.7%
-8.8%$12.96B$2.88B11.611,305Positive News
Analyst Forecast
ALNY
Alnylam Pharmaceuticals
4.2888 of 5 stars
$313.13
+1.1%
$319.58
+2.1%
+32.4%$40.83B$2.25B-149.822,230Positive News
Analyst Forecast
BIIB
Biogen
4.9742 of 5 stars
$124.76
-1.8%
$188.19
+50.8%
-43.9%$18.28B$9.68B12.327,605
INCY
Incyte
4.3669 of 5 stars
$67.26
-1.8%
$74.53
+10.8%
+12.9%$13.02B$4.41B210.192,617
NBIX
Neurocrine Biosciences
4.9388 of 5 stars
$125.80
-0.6%
$162.00
+28.8%
-8.6%$12.45B$2.36B42.641,800Positive News
EXEL
Exelixis
4.7384 of 5 stars
$43.37
+7.4%
$41.00
-5.5%
+96.0%$11.83B$2.17B19.711,147Positive News
Analyst Forecast
Gap Up
High Trading Volume
BMRN
BioMarin Pharmaceutical
4.9455 of 5 stars
$54.08
-1.7%
$93.45
+72.8%
-31.6%$10.37B$2.95B20.103,040
EXAS
Exact Sciences
4.8814 of 5 stars
$52.54
-0.9%
$70.90
+34.9%
+28.7%$9.91B$2.76B-9.547,000Analyst Revision
RGEN
Repligen
4.7966 of 5 stars
$120.11
+1.1%
$173.25
+44.2%
+2.5%$6.75B$634.44M-266.911,778Positive News
Analyst Downgrade
HALO
Halozyme Therapeutics
4.8482 of 5 stars
$52.80
0.0%
$61.90
+17.2%
+1.7%$6.51B$1.02B14.04390Analyst Revision
MDGL
Madrigal Pharmaceuticals
3.9702 of 5 stars
$282.99
-1.0%
$420.63
+48.6%
+7.5%$6.28B$180.13M-15.6890

Related Companies and Tools


This page (NASDAQ:UTHR) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners